MAIN MOLECULAR TARGETS FOR PROSTATE CANCER THERAPY
Androgenic pathway plays a pivotal role in the development of benign and malignant prostate tumors. Most of the prostate neoplasms are hormone-dependent at the time of diagnosis. Therapeutic interventions aimed at reducing the level of testosterone in the blood allow to stop progression of the disea...
Saved in:
| Main Authors: | G. S. Krasnov, A. A. Dmitriev, N. N. Volchenko, T. V. Danilova, A. F. Sadritdinova, A. V. Snezhkina, N. V. Melnikova, M. S. Fedorova, V. A. Lakunina, A. A. Belova, B. Y. Alekseev, A. D. Kaprin, A. V. Kudryavtseva |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2016-02-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/286 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
SURVIVAL EFFECT OF PALLIATIVE RADIOTHERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DEVELOPING OLIGO-PROGRESSION UNDER ANTIANDROGEN TREATMENT
by: Sabin Göktaş Aydın, et al.
Published: (2023-03-01) -
Short-term efficacy of enzalutamide in treatment of patients with abiraterone-resistant metastatic castration-resistant prostate cancer
by: MEI Jingchang, SU Xiaonan, YAO Yu, GUAN Fengju, ZHANG Guiming
Published: (2025-02-01) -
Abiraterone and Galeterone, Powerful Tools Against Prostate Cancer: Present and Perspective
by: Ivana Z. Kuzminac, et al.
Published: (2024-10-01) -
Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2019-01-01) -
Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings
by: Armen Aprikian, et al.
Published: (2025-02-01)